Abstract: TH-PO887
Prevalence of CKD: Comparison of Real-World Data (RWD) Sources to the US National Health and Nutrition Examination Survey (NHANES)
Session Information
- CKD: Epidemiology, Risk Factors, Prevention - I
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention
Authors
- Stavas, Joseph, ProKidney, Raleigh, North Carolina, United States
- Butler, Emily Lynn, ProKidney, Raleigh, North Carolina, United States
- Irwin, Debra E., Aetion, New York, New York, United States
- Shah, Rohan J., Aetion, New York, New York, United States
- Latimer, Helen, Aetion, New York, New York, United States
- Sepulveda, Alberto, Royalty Pharma, New York, New York, United States
- Balkin, Sandy D., Royalty Pharma, New York, New York, United States
- Tuttle, Katherine R., Providence Health System, Spokane, Washington, United States
Background
NHANES is a common source of CKD prevalence data in the USA, where CKD stage is based on one eGFR estimate using the KDIGO categories. We estimated the prevalence of CKD stage ≥3 using RWD and compared it to NHANES estimates.
Methods
RWD was extracted from HealthVerity PrivateSource20 closed claims and linked to Veradigm Health Insights Electronic Health Record (EHR). Adults, ≥20 years old, continuously enrolled in the claims data and active in the EHR were evaluated during 2018. eGFR values were used to determine the CKD stage. The prevalence of CKD stage ≥3 was projected to the USA population (standardized on age, gender, and geographic region using USA census data) and compared to the NHANES 2015-2018 report.
Results
The prevalence of all CKD stage ≥3 estimated in RWD was significantly lower than NHANES reports (see table). This finding translates into 22.5 million individuals estimated from NHANES and 5.2 million from RWD. The absolute differences between the two groups were less for higher categories.
Conclusion
Prevalence estimates from our RWD sources included those who have continuous health insurance, sought healthcare, and were diagnosed with CKD. In contrast, NHANES sampled a more diverse population likely to be covered by various forms of insurance including the uninsured. This work supports the unmet need for early identification of CKD and demonstrates necessity for methodological clarity when reporting prevalence estimates.
Prevalence of CKD stages
| SOURCE | Stage 3-5 | Stage 3 | Stage 4 | Stage 5 |
| NHANES | 7% | 6.4% | 0.4% | 0.1% |
| Real World Data | 2%* | 1.8%* | 0.1%* | 0.05%* |
*p < 0.05
Funding
- Commercial Support – ProKidney, LLC